Skip to main content
OSTX logo

OSTX · OS Therapies Inc

$1.53 +0.03 (+2.00%) At close · Jul 17
Market Cap
$68.14M
Shares
44,538,106

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income
-$28.75M -223.7%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$0.98 +23.4%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$14.24M -95.5%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023
$22.4M $16.36M $2.84M $3.22M
$11.47M $12.34M $3.97M $1.13M
$363.09K $2780
-$33.87M -$28.71M -$6.81M -$4.34M
$2.05M $3.45M
$228 $249 $2
-$1.4M -$48.14K -$2.07M -$3.45M
-$35.27M -$28.75M -$8.88M -$7.79M
-$35.27M -$28.75M -$8.91M -$7.92M
USD/shares -$0.98 -$1.28 -$1.46
USD/shares -$0.98 -$1.28 -$1.46
shares 12.38M 5.43M
shares 29.25M 6.95M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.75×
EV/EBIT
Biotechnology median 26.36×
P/E (TTM)
Biotechnology median 7.37×

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31
Chief Operating Decision Maker -$28,705,701 -$6,813,846
All Other Segments -$4,342,645
Key facts CIK 1795091 CUSIP 68764Y207 13F (30d) 2 filings 2 filers Visit website Investor relations